Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,750	326 Pages	Arizton Advisory and Intelligence	April, 2022	ARZ17146842

Best Price Guarantee
Price	from $3,750
Length	326 Pages
Publisher	Arizton Advisory and Intelligence
Published Date	April, 2022
SKU	ARZ17146842

Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027

The study considers a detailed scenario of the present global anti-inflammatory drugs market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

The global anti-inflammatory drugs market is expected to grow at a CAGR of 6.78% during 2022-2027

MARKET GROWTH AND OPPORTUNITIES

Rising OTC Buying behavior of Anti-inflammatory drugs Among Larger Patient Groups
Rising Prevalence of a Broad Range of Inflammatory Diseases
Increasing Use of Biologics for Treating Inflammatory Diseases

GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SHARE AND SEGMENTS

Based on drug class, biologics and biosimilars is the major contributor in the global anti-inflammatory drugs market, and it is likely to witness high incremental growth of $33.64 billion during the forecast period.
The global anti-inflammatory drugs market is highly competitive and fragmented even though the leading companies are constantly consolidating their market position through strategic and high-profile mergers and acquisitions.

Segmentation by Drug Class

Biologics & Biosimilars
NSAIDs
Steroids
Others

Segmentation by Application

Autoimmune Diseases
Respiratory Diseases
Others

Segmentation by Route of Administration

Parenteral
Oral
Topical
Inhalation

GEOGRAPHICAL ANALYSIS

In 2021, North America was the major revenue contributor and accounted for 41.38% in the global anti-inflammatory drugs market in 2021 and witness the highest incremental growth of $20.88 billion during the forecast period.

Increasing population, the emergence of autoimmune diseases, expansion of demand, increase in pharma and biopharma facilities, and the advent of COVID-19 are major factors to boost the demand for anti-inflammatory drugs in Europe.

Segmentation by Geography

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

APAC

China

India

Japan

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

Turkey

VENDOR ANALYSIS

Key Vendors

AbbVie
Amgen
Biogen
Bristol Myers Squibb
Eli Lilly & Company
F. Hoffmann-La Roche
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Novartis
Pfizer

Other Prominent Vendors

Actiza Pharmaceutical
Allergan
Antibe Therapeutics
Aurinia Pharmaceuticals
AstraZeneca
Aurobindo Pharma
Bayer
Bio-Thera Solutions
Cadila Pharmaceuticals
Cipla
Celltrion
CENTURION REMEDIES
Dr. Reddy's Laboratories
Eisai
Gilead Sciences
Glenmark Pharmaceuticals
Lupin
Medico Remedies
Regeneron Pharmaceuticals
Samsung Bioepis
Sanofi
Sun Pharmaceutical Industries
Swedish Orphan Biovitrum
UCB
FUJIFILM KYOWA KIRIN BIOLOGICS
Teva pharmaceuticals

1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE: 4.1 MARKET DEFINITION; 4.1.1 INCLUSIONS; 4.1.2 EXCLUSIONS; 4.1.3 MARKET ESTIMATION CAVEATS; 4.2 BASE YEAR; 4.3 SCOPE OF THE STUDY; 4.4 MARKET SEGMENTATION; 4.4.1 MARKET SEGMENTATION BY DRUG CLASS; 4.4.2 MARKET SEGMENTATION BY APPLICATION; 4.4.3 MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION; 4.4.4 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS: 5.1 KEY CAVEATS; 5.2 CURRENCY CONVERSION; 5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION: 7.1 OVERVIEW; 7.1.1 EPIDEMIOLOGY OF INFLAMMATORY DISEASES; 7.1.2 TREATMENT OF INFLAMMATORY DISEASES
8 MARKET OPPORTUNITIES & TRENDS: 8.1 PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES; 8.2 SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES; 8.3 RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS
9 MARKET GROWTH ENABLERS: 9.1 PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS; 9.2 RISING PREVALENCE OF INFLAMMATORY DISEASES; 9.3 GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES
10 MARKET RESTRAINTS: 10.1 PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS; 10.2 SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS; 10.3 PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES
11 MARKET LANDSCAPE: 11.1 MARKET OVERVIEW; 11.1.1 MARKET SIZE & FORECAST; 11.1.2 INSIGHTS BY GEOGRAPHY; 11.1.3 INSIGHTS BY DRUG CLASS; 11.1.4 INSIGHTS BY APPLICATION; 11.1.5 INSIGHTS BY ROUTE OF ADMINISTRATION; 11.2 FIVE FORCES ANALYSIS; 11.2.1 THREAT OF NEW ENTRANTS; 11.2.2 BARGAINING POWER OF SUPPLIERS; 11.2.3 BARGAINING POWER OF BUYERS; 11.2.4 THREAT OF SUBSTITUTES; 11.2.5 COMPETITIVE RIVALRY
12 DRUG CLASS: 12.1 MARKET SNAPSHOT & GROWTH ENGINE; 12.2 MARKET OVERVIEW; 12.3 BIOLOGICS & BIOSIMILARS; 12.3.1 MARKET OVERVIEW; 12.3.2 MARKET SIZE & FORECAST; 12.4 NSAIDS; 12.4.1 MARKET OVERVIEW; 12.4.2 MARKET SIZE & FORECAST; 12.5 STEROIDS; 12.5.1 MARKET OVERVIEW; 12.5.2 MARKET SIZE & FORECAST; 12.1 OTHERS; 12.1.1 MARKET OVERVIEW; 12.1.2 MARKET SIZE & FORECAST
13 APPLICATION: 13.1 MARKET SNAPSHOT & GROWTH ENGINE; 13.2 MARKET OVERVIEW; 13.3 AUTOIMMUNE DISEASES; 13.3.1 MARKET OVERVIEW; 13.3.2 MARKET SIZE & FORECAST; 13.4 RESPIRATORY DISEASES; 13.4.1 MARKET OVERVIEW; 13.4.2 MARKET SIZE & FORECAST; 13.5 OTHERS; 13.5.1 MARKET OVERVIEW; 13.5.2 MARKET SIZE & FORECAST
14 ROUTE OF ADMINISTRATION: 14.1 MARKET SNAPSHOT & GROWTH ENGINE; 14.2 MARKET OVERVIEW; 14.3 PARENTERAL; 14.3.1 MARKET OVERVIEW; 14.3.2 MARKET SIZE & FORECAST; 14.4 ORAL; 14.4.1 MARKET OVERVIEW; 14.4.2 MARKET SIZE & FORECAST; 14.5 TOPICAL; 14.5.1 MARKET OVERVIEW; 14.5.2 MARKET SIZE & FORECAST; 14.6 INHALATION; 14.6.1 MARKET OVERVIEW; 14.6.2 MARKET SIZE & FORECAST
15 GEOGRAPHY: 15.1 MARKET SNAPSHOT & GROWTH ENGINE; 15.2 GEOGRAPHIC OVERVIEW
16 NORTH AMERICA: 16.1 MARKET OVERVIEW; 16.2 MARKET SIZE & FORECAST; 16.2.1 NORTH AMERICA: DRUG CLASS SEGMENTATION; 16.2.2 NORTH AMERICA: INDICATION SEGMENTATION; 16.2.3 NORTH AMERICA: ROUTE OF ADMINISTERATION SEGMENTATION; 16.3 KEY COUNTRIES; 16.3.1 US: MARKET SIZE & FORECAST; 16.3.2 CANADA: MARKET SIZE & FORECAST
17 EUROPE: 17.1 MARKET OVERVIEW; 17.2 MARKET SIZE & FORECAST; 17.2.1 EUROPE: DRUG CLASS SEGMENTATION; 17.2.2 EUROPE: APPLICATION SEGMENTATION; 17.2.3 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION; 17.3 KEY COUNTRIES; 17.3.1 GERMANY: MARKET SIZE & FORECAST; 17.3.2 THE UK: MARKET SIZE & FORECAST; 17.3.3 FRANCE: MARKET SIZE & FORECAST; 17.3.4 ITALY: MARKET SIZE & FORECAST; 17.3.5 SPAIN: MARKET SIZE & FORECAST
18 APAC: 18.1 MARKET OVERVIEW; 18.2 MARKET SIZE & FORECAST; 18.2.1 APAC: DRUG CLASS SEGMENTATION; 18.2.2 APAC: APPLICATION SEGMENTATION; 18.2.3 APAC: ROUTE OF ADMINISTERATION SEGMENTATION; 18.3 KEY COUNTRIES; 18.3.1 CHINA: MARKET SIZE & FORECAST; 18.3.2 JAPAN: MARKET SIZE & FORECAST; 18.3.3 INDIA: MARKET SIZE & FORECAST; 18.3.4 AUSTRALIA: MARKET SIZE & FORECAST; 18.3.5 SOUTH KOREA: MARKET SIZE & FORECAST
19 LATIN AMERICA: 19.1 MARKET OVERVIEW; 19.2 MARKET SIZE & FORECAST; 19.2.1 LATIN AMERICA: DRUG CLASS SEGMENTATION; 19.2.2 LATIN AMERICA: APPLICATION SEGMENTATION; 19.2.3 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION; 19.3 KEY COUNTRIES; 19.3.1 BRAZIL: MARKET SIZE & FORECAST; 19.3.2 MEXICO: MARKET SIZE & FORECAST; 19.3.3 ARGENTINA : MARKET SIZE & FORECAST
20 MIDDLE EAST AND AFRICA: 20.1 MARKET OVERVIEW; 20.2 MARKET SIZE & FORECAST; 20.2.1 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION; 20.2.2 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION; 20.2.3 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTERATION SEGMENTATION; 20.3 KEY COUNTRIES; 20.3.1 TURKEY: MARKET SIZE & FORECAST; 20.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST; 20.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST
21 COMPETITIVE LANDSCAPE: 21.1 COMPETITION OVERVIEW; 21.2 MARKET SHARE ANALYSIS
22 KEY COMPANIES PROFILES: 22.1 ABBVIE; 22.1.1 BUSINESS OVERVIEW; 22.1.2 PRODUCT OFFERINGS; 22.1.3 KEY STRATEGIES; 22.1.4 KEY STRENGTHS; 22.1.5 KEY OPPORTUNITIES; 22.2 AMGEN; 22.2.1 BUSINESS OVERVIEW; 22.2.2 PRODUCT OFFERINGS; 22.2.3 KEY STRATEGIES; 22.2.4 KEY STRENGTHS; 22.2.5 KEY OPPORTUNITIES; 22.3 BIOGEN; 22.3.1 BUSINESS OVERVIEW; 22.3.2 PRODUCT OFFERINGS; 22.3.3 KEY STRATEGIES; 22.3.4 KEY STRENGTHS; 22.3.5 KEY OPPORTUNITIES; 22.4 BRISTOL MYERS SQUIBB; 22.4.1 BUSINESS OVERVIEW; 22.4.2 PRODUCT OFFERINGS; 22.4.3 KEY STRATEGIES; 22.4.4 KEY STRENGTHS; 22.4.5 KEY OPPORTUNITIES; 22.5 ELI LILLY & COMPANY; 22.5.1 BUSINESS OVERVIEW; 22.5.2 PRODUCT OFFERINGS; 22.5.3 KEY STRATEGIES; 22.5.4 KEY STRENGTHS; 22.5.5 KEY OPPORTUNITIES; 22.6 F. HOFFMANN-LA ROCHE; 22.6.1 BUSINESS OVERVIEW; 22.6.2 PRODUCT OFFERINGS; 22.6.3 KEY STRATEGIES; 22.6.4 KEY STRENGTHS; 22.6.5 KEY OPPORTUNITIES; 22.7 GLAXOSMITHKLINE; 22.7.1 BUSINESS OVERVIEW; 22.7.2 PRODUCT OFFERINGS; 22.7.3 KEY STRATEGIES; 22.7.4 KEY STRENGTHS; 22.7.5 KEY OPPORTUNITIES; 22.8 JOHNSON & JOHNSON; 22.8.1 BUSINESS OVERVIEW; 22.8.2 PRODUCT OFFERINGS; 22.8.3 KEY STRATEGIES; 22.8.4 KEY STRENGTHS; 22.8.5 KEY OPPORTUNITIES; 22.9 MERCK & CO; 22.9.1 BUSINESS OVERVIEW; 22.9.2 PRODUCT OFFERINGS; 22.9.3 KEY STRATEGIES; 22.9.4 KEY STRENGTHS; 22.9.5 KEY OPPORTUNITIES; 22.10 NOVARTIS; 22.10.1 BUSINESS OVERVIEW; 22.10.2 PRODUCT OFFERINGS; 22.10.3 KEY STRATEGIES; 22.10.4 KEY STRENGTHS; 22.10.5 KEY OPPORTUNITIES; 22.11 PFIZER; 22.11.1 BUSINESS OVERVIEW; 22.11.2 PRODUCT OFFERINGS; 22.11.3 KEY STRATEGIES; 22.11.4 KEY STRENGTHS; 22.11.5 KEY OPPORTUNITIES
23 OTHER PROMINENT VENDORS: 23.1 ACTIZA PHARMACEUTICAL; 23.1.1 BUSINESS OVERVIEW; 23.1.2 PRODUCT OFFERINGS; 23.2 ALLERGAN; 23.2.1 BUSINESS OVERVIEW; 23.2.2 PRODUCT OFFERINGS; 23.3 ANTIBE THERAPEUTICS; 23.3.1 BUSINESS OVERVIEW; 23.3.2 PRODUCT OFFERINGS; 23.4 AURINIA PHARMACEUTICALS; 23.4.1 BUSINESS OVERVIEW; 23.4.2 PRODUCT OFFERINGS; 23.5 ASTRAZENECA; 23.5.1 BUSINESS OVERVIEW; 23.5.2 PRODUCT OFFERINGS; 23.6 AUROBINDO PHARMA; 23.6.1 BUSINESS OVERVIEW; 23.6.2 PRODUCT OFFERINGS; 23.7 BAYER; 23.7.1 BUSINESS OVERVIEW; 23.7.2 PRODUCT OFFERINGS; 23.8 BIO-THERASOLUTIONS; 23.8.1 BUSINESS OVERVIEW; 23.8.2 PRODUCT OFFERINGS; 23.9 CADILA PHARMACEUTICALS; 23.9.1 BUSINESS OVERVIEW; 23.9.2 PRODUCT OFFERINGS; 23.10 CIPLA; 23.10.1 BUSINESS OVERVIEW; 23.10.2 PRODUCT OFFERINGS; 23.11 CELLTRION; 23.11.1 BUSINESS OVERVIEW; 23.11.2 PRODUCT OFFERINGS; 23.12 CENTURION REMEDIES; 23.12.1 BUSINESS OVERVIEW; 23.12.2 PRODUCT OFFERINGS; 23.13 DR. REDDY’S LABORATORIES; 23.13.1 BUSINESS OVERVIEW; 23.13.2 PRODUCT OFFERINGS; 23.14 EISAI; 23.14.1 BUSINESS OVERVIEW; 23.15 GILEAD SCIENCES; 23.15.1 BUSINESS OVERVIEW; 23.16 GLENMARK PHARMACEUTICALS; 23.16.1 BUSINESS OVERVIEW; 23.16.2 PRODUCT OFFERINGS; 23.17 LUPIN; 23.17.1 BUSINESS OVERVIEW; 23.17.2 PRODUCT OFFERINGS; 23.18 MEDICO REMEDIES; 23.18.1 BUSINESS OVERVIEW; 23.18.2 PRODUCT OFFERINGS; 23.19 REGENERON PHARMACEUTICALS; 23.19.1 BUSINESS OVERVIEW; 23.19.2 PRODUCT OFFERINGS; 23.20 SAMSUNG BIOEPIS; 23.20.1 BUSINESS OVERVIEW; 23.20.2 PRODUCT OFFERINGS; 23.21 SANOFI; 23.21.1 BUSINESS OVERVIEW; 23.21.2 PRODUCT OFFERINGS; 23.22 SUN PHARMACEUTICAL INDUSTRIES; 23.22.1 BUSINESS OVERVIEW; 23.22.2 PRODUCT OFFERINGS; 23.23 SWEDISH ORPHAN BIOVITRUM; 23.23.1 BUSINESS OVERVIEW; 23.23.2 PRODUCT OFFERINGS; 23.24 UCB; 23.24.1 BUSINESS OVERVIEW; 23.24.2 PRODUCT OFFERINGS; 23.25 FUJIFILM KYOWA KIRIN BIOLOGICS; 23.25.1 BUSINESS OVERVIEW; 23.25.2 PRODUCT OFFERINGS
24 REPORT SUMMARY: 24.1 KEY TAKEAWAYS; 24.2 STRATEGIC RECOMMENDATIONS
25 QUANTITATIVE SUMMARY: 25.1 MARKET BY DRUG CLASS; 25.1.1 NORTH AMERICA: DRUG CLASS SEGMENTATION; 25.1.3 EUROPE: DRUG CLASS SEGMENTATION; 25.1.4 APAC: DRUG CLASS SEGMENTATION; 25.1.5 LATIN AMERICA: DRUG CLASS SEGMENTATION; 25.1.6 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION; 25.2 MARKET BY APPLICATION; 25.2.1 NORTH AMERICA: APPLICATION SEGMENTATION; 25.2.2 EUROPE: APPLICATION SEGMENTATION; 25.2.3 APAC: APPLICATION SEGMENTATION; 25.2.4 LATIN AMERICA: APPLICATION SEGMENTATION; 25.2.5 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION; 25.3 MARKET BY ROUTE OF ADMINISTRATION; 25.3.1 NORTH AMERICA: ROUTE OF ADMINISTRATION; 25.3.2 EUROPE: ROUTE OF ADMINISTRATION; 25.3.3 APAC: ROUTE OF ADMINISTRATION; 25.3.4 LATIN AMERICA: ROUTE OF ADMINISTRATION; 25.3.5 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTRATION; 25.4 MARKET BY GEOGRAPHY; 25.5.1 BIOLOGICS & BIOSIMILARS: GEOGRAPHY SEGMENTATION; 25.5.2 NSAIDS: GEOGRAPHY SEGMENTATION; 25.5.3 STEROIDS: GEOGRAPHY SEGMENTATION; 25.5.4 OTHERS: GEOGRAPHY SEGMENTATION; 25.5.5 AUTOIMMUNE DISEASES: GEOGRAPHY SEGMENTATION; 25.5.6 RESPIRATORY DISEASES: GEOGRAPHY SEGMENTATION; 25.5.7 OTHER DISEASES: GEOGRAPHY SEGMENTATION; 25.5.8 PARENTERAL: GEOGRAPHY SEGMENTATION; 25.5.9 ORAL: GEOGRAPHY SEGMENTATION; 25.5.10 TOPICAL: GEOGRAPHY SEGMENTATION; 25.5.11 INHALATIONAL: GEOGRAPHY SEGMENTATION
26 APPENDIX: 26.1 ABBREVIATIONS